劉偉 1 , 安杰 2 , 張超 1
  • 1. 第三軍醫(yī)大學(xué)西南醫(yī)院普外科（重慶400038）;;
  • 2.北京軍區(qū)白求恩國(guó)際和平醫(yī)院病理科（河北石家莊050082）;

【摘要】目的 探討選擇性環(huán)氧合酶2（COX2）抑制劑——尼美舒利對(duì)體外培養(yǎng)的結(jié)腸癌細(xì)胞的生長(zhǎng)及對(duì)基質(zhì)金屬蛋白酶2（MMP2）表達(dá)的影響。 方法 實(shí)驗(yàn)分為尼美舒利組、二甲亞砜（DMSO）對(duì)照組及不接種細(xì)胞的空白對(duì)照組，采用MTT法檢測(cè)不同濃度的尼美舒利對(duì)人結(jié)腸癌細(xì)胞株HT29(COX2高表達(dá))及HCT116(COX2低表達(dá))增殖的抑制效應(yīng)； 采用改良明膠酶譜分析法檢測(cè)MMP2的表達(dá)。 結(jié)果 尼美舒利對(duì)人結(jié)腸癌細(xì)胞株HT29和HCT116生長(zhǎng)的抑制作用呈時(shí)間、劑量依賴(lài)性，且對(duì)HT29細(xì)胞的抑制作用強(qiáng)于HCT116細(xì)胞；尼美舒利抑制了HT29細(xì)胞的MMP2表達(dá)，而對(duì)HCT116細(xì)胞MMP2的表達(dá)的抑制作用不明顯。 結(jié)論 尼美舒利可明顯抑制COX2高表達(dá)的結(jié)腸癌細(xì)胞株HT29的增殖和生長(zhǎng)，提示尼美舒利可能通過(guò)抑制COX2活性而降低細(xì)胞MMP2的表達(dá)。

引用本文： 劉偉,安杰,張超. 尼美舒利對(duì)結(jié)腸腺癌細(xì)胞MMP-2表達(dá)的影響. 中國(guó)普外基礎(chǔ)與臨床雜志, 2005, 12(6): 585-588. doi: 復(fù)制

1. 1 Fujita T, Matsui M, Takaku K, et al. Size  and invasiondependent increase in cyclooxygenase 2 levels in human colorectal carcinomas [Ｊ]. Cancer Res， 1998; 58(21)48232 Mook OR, Frederiks WM, Van Noorden CJ. The role of gelatinases in colorectal cancer progression and metastasis [Ｊ]. Biochim Biophys Acta, 2004; 1705(2)693 Reddy BS, Rao CV. Colon cancer: a role for cyclooxygenase2specific nonsteroidal antiinflammatory drugs [Ｊ]. Drugs Aging, 2000; 16(5)3294 Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2 [Ｊ]. Cell, 1995; 83(3)4935 Piazza GA, Rahm AK, Finn TS, et al. Apoptosis primarily accounts for the growthinhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction [Ｊ]. Cancer Res, 1997; 57(12)24526 Shiff SJ, Qiao L, Tsai LL, et al. Sulindac sulfide, an aspirinlike compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT29 colon adenocarcinoma cells [Ｊ]. J Clin Invest, 1995; 96(1)4917 Kleiner DE, StetlerStevenson WG. Matrix metalloproteinases and metastasis [Ｊ]. Cancer Chemother Pharmacol, 1999; 43(Suppl)S428 Wu J, Akaike T, Hayashida K, et al. Enhanced vascular permeability in solid tumor involving peroxynitrite and matrix metalloproteinases [Ｊ]. Jpn J Cancer Res, 2001; 92(4)4399 Oba K, Konno H, Tanaka T, et al. Prevention of liver metastasis of human colon cancer by selective matrix metalloproteinase inhibitor MMI166 [Ｊ]. Cancer Lett, 2002; 175(1)4510 Papadopoulou S, Scorilas A, Arnogianaki N, et al. Expression of gelatinaseA (MMP2) in human colon cancer and normal colon mucosa [Ｊ]. Tumour Biol, 2001; 22(6)38311 Ko K, Yazumi S, Yoshikawa K, et al. Activation of fibroblastderived matrix metalloproteinase2 by coloncancer cells in noncontact Cocultures [Ｊ]. Int J Cancer, 2000; 87(2)16512 Li G, Yang T, Yan J. Cyclooxygenase-2 increased the angiogenic and metastatic potential of tumor cells [Ｊ]. Biochem Biophys Res Commun， 2002; 299(5)886.
  1. 1. 1 Fujita T, Matsui M, Takaku K, et al. Size  and invasiondependent increase in cyclooxygenase 2 levels in human colorectal carcinomas [Ｊ]. Cancer Res， 1998; 58(21)48232 Mook OR, Frederiks WM, Van Noorden CJ. The role of gelatinases in colorectal cancer progression and metastasis [Ｊ]. Biochim Biophys Acta, 2004; 1705(2)693 Reddy BS, Rao CV. Colon cancer: a role for cyclooxygenase2specific nonsteroidal antiinflammatory drugs [Ｊ]. Drugs Aging, 2000; 16(5)3294 Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2 [Ｊ]. Cell, 1995; 83(3)4935 Piazza GA, Rahm AK, Finn TS, et al. Apoptosis primarily accounts for the growthinhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction [Ｊ]. Cancer Res, 1997; 57(12)24526 Shiff SJ, Qiao L, Tsai LL, et al. Sulindac sulfide, an aspirinlike compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT29 colon adenocarcinoma cells [Ｊ]. J Clin Invest, 1995; 96(1)4917 Kleiner DE, StetlerStevenson WG. Matrix metalloproteinases and metastasis [Ｊ]. Cancer Chemother Pharmacol, 1999; 43(Suppl)S428 Wu J, Akaike T, Hayashida K, et al. Enhanced vascular permeability in solid tumor involving peroxynitrite and matrix metalloproteinases [Ｊ]. Jpn J Cancer Res, 2001; 92(4)4399 Oba K, Konno H, Tanaka T, et al. Prevention of liver metastasis of human colon cancer by selective matrix metalloproteinase inhibitor MMI166 [Ｊ]. Cancer Lett, 2002; 175(1)4510 Papadopoulou S, Scorilas A, Arnogianaki N, et al. Expression of gelatinaseA (MMP2) in human colon cancer and normal colon mucosa [Ｊ]. Tumour Biol, 2001; 22(6)38311 Ko K, Yazumi S, Yoshikawa K, et al. Activation of fibroblastderived matrix metalloproteinase2 by coloncancer cells in noncontact Cocultures [Ｊ]. Int J Cancer, 2000; 87(2)16512 Li G, Yang T, Yan J. Cyclooxygenase-2 increased the angiogenic and metastatic potential of tumor cells [Ｊ]. Biochem Biophys Res Commun， 2002; 299(5)886.